Ultragenyx Pharmaceu (RARE) Stock Price, Quote & News

Company Profile

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevi...

Industry: Biotechnology

Sector: Healthcare

Phone: 415 483 8800

Website: www.ultragenyx.com

Address:

60 Leveroni Court, Novato, United States

RandomInvestor777 Jun. 22 at 5:42 PM

$RARE Considering all patients would have be at 338 days at july, wouldn't readout be closer to early august? kindly anyone who's in depth about this company tell me if true or otherwise.

1 · Reply

Cascas007 Jun. 18 at 3:39 PM

$RARE This is a $15B company if Angelman phase 3 data comes out strong

0 · Reply

Pharma3000 Jun. 15 at 3:14 PM

$RARE

0 · Reply

Pharma3000 Jun. 15 at 3:13 PM

$RARE

0 · Reply

LDT79 Jun. 11 at 4:16 PM

$RARE if they raise they could buy $MREO for peanuts

1 · Reply

lonelywarrior Jun. 10 at 6:07 PM

$RARE Still cheap, good entry levels.

0 · Reply

AIBioScanner Jun. 8 at 7:58 AM

$RARE AI-Based Findings on RARE After running RARE through my AI-driven quantitative framework, the stock is in a downtrend with price falling below both moving averages amid weakening momentum. RARE is trading around $21.91, below both the 20-day (~$23.98) and 50-day (~$23.77) moving averages — indicating continued selling pressure and softening structure. Key signals: • Trading below both MAs — downtrend • MACD negative (-0.52) — bearish momentum • Range between ~$21.78 support and ~$26.84 resistance 1-Month Outlook: Base scenario: consolidation near $20.81–$23.01 Breakout above $23.01 could open a move toward $26.92 Breakdown below $20.81 may extend further downside toward $17.07 Structure is bearish. Requires significant catalyst or volume reversal for recovery. Not financial advice.$RARE

0 · Reply

LDT79 Jun. 3 at 6:36 PM

$RARE can this thing stop fading every fucking morning?

0 · Reply

traderjon01 Jun. 3 at 5:29 PM

$MREO adding the dip here. This is $OTLK 2.0 The Ultimate Asymmetric Rare-Disease Play * The Setrusumab Pivot (Partnered with $RARE is a $2B market cap stock working with a penny stock 👀🤔 ) * The Catalyst: They achieved high statistical significance on Bone Mineral Density (BMD). * The Upside: There are zero FDA-approved treatments for Osteogenesis Imperfecta (OI). FDA & EMA are currently in discussions regarding a path forward using the robust BMD data. Flexibility here is an instant game-changer. * Management aggressively cut pre-commercialization and manufacturing costs post-data. * Quarterly net loss was cut nearly in half ($6.7M vs $12.9M YoY). * Cash runway now extends comfortably into mid-2027, removing near-term dilution risk. * Asset for AATD lung disease has Fast Track & Orphan status. * Phase 3 trial design is already aligned with both the FDA and EMA.

0 · Reply

LDT79 Jun. 2 at 3:43 PM

$RARE fuck is going on here?? Emil Kakkis, get shit done my man!!!

0 · Reply

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jun 9, 2026, 4:00 PM EDT - 13 days ago

Ultragenyx Pharmaceutical Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 3, 2026, 4:30 PM EDT - 19 days ago

Ultragenyx to Participate at Goldman Sachs 47th Annual Global Healthcare Conference

2026-05-21T11:16:33.000Z - 4 weeks ago

Ultragenyx price target raised to $96 from $84 at Cantor Fitzgerald

May 14, 2026, 11:30 AM EDT - 5 weeks ago

Ultragenyx Pharmaceutical Transcript: AGM 2026

May 12, 2026, 5:20 PM EDT - 5 weeks ago

Ultragenyx Pharmaceutical Transcript: Bank of America Global Healthcare Conference 2026

2026-05-11T16:15:56.000Z - 6 weeks ago

Ultragenyx price target lowered to $33 from $34 at Evercore ISI

2026-05-08T13:52:56.000Z - 6 weeks ago

Ultragenyx price target lowered to $26 from $27 at Wedbush

2026-05-08T13:31:39.000Z - 6 weeks ago

Ultragenyx price target lowered to $43 from $52 at Guggenheim

May 7, 2026, 4:00 PM EDT - 6 weeks ago

Rare disease families find roadmap to drug development at bootcamps.

May 7, 2026, 6:30 AM EDT - 6 weeks ago

Rare disease families find roadmap to drug development at bootcamps

May 6, 2026, 4:30 PM EDT - 6 weeks ago

Ultragenyx to Participate at Bank of America's 2026 Healthcare Conference

May 5, 2026, 5:00 PM EDT - 6 weeks ago

Ultragenyx Pharmaceutical Earnings Call Transcript: Q1 2026

May 5, 2026, 5:00 PM EDT - 6 weeks ago

Ultragenyx Pharmaceutical Earnings release: Q1 2026

May 5, 2026, 5:00 PM EDT - 6 weeks ago

Ultragenyx Pharmaceutical Quarterly report: Q1 2026

May 5, 2026, 4:01 PM EDT - 6 weeks ago

Ultragenyx Reports First Quarter 2026 Financial Results and Corporate Update

May 5, 2026, 7:00 AM EDT - 7 weeks ago

Ultragenyx Pharmaceutical Slides: Corporate presentation

Apr 30, 2026, 8:00 AM EDT - 7 weeks ago

Ultragenyx Pharmaceutical Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 7 weeks ago

Ultragenyx to Host Conference Call for First Quarter 2026 Financial Results and Corporate Update

2026-04-29T09:45:53.000Z - 7 weeks ago

Ultragenyx price target lowered to $43 from $44 at Barclays

2026-04-16T12:35:15.000Z - 2 months ago

Ultragenyx price target raised to $67 from $50 at Morgan Stanley

Apr 3, 2026, 9:43 AM EDT - 2 months ago

DEADLINE NEXT WEEK: Berger Montague Advises Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) Investors to Contact the Firm Before April 6, 2026

2026-04-02T13:06:11.000Z - 2 months ago

Ultragenyx UX111 AAV9 biologics license application accepted for FDA review

2026-03-30T13:27:59.000Z - 3 months ago

Ultragenyx announces FDA clearance of UX016 investigational new drug application

Mar 30, 2026, 8:30 AM EDT - 3 months ago

Ultragenyx Announces FDA Clearance of Investigational New Drug (IND) Application for UX016, a Sialic Acid Prodrug for the Treatment of GNE Myopathy

Mar 27, 2026, 8:00 AM EDT - 3 months ago

Ultragenyx Pharmaceutical Proxy statement: Proxy filing

Mar 27, 2026, 8:00 AM EDT - 3 months ago

Ultragenyx Pharmaceutical Proxy statement: Proxy filing

2026-03-24T08:35:19.000Z - 3 months ago

Ultragenyx downgraded to Neutral from Buy at Goldman Sachs

2026-03-18T15:57:48.000Z - 3 months ago

Ultragenyx Facing Shareholder Lawsuit over Brittle Bone Disease Drug Claims

Mar 12, 2026, 8:47 AM EDT - 3 months ago

Ultragenyx's gene therapy helps control ammonia levels in late-stage study

2026-03-12T12:36:18.000Z - 3 months ago

Ultragenyx Phase 3 Enh3ance study showed statistically significant results

2026-03-12T10:54:43.000Z - 3 months ago

Ultragenyx price target lowered to $74 from $120 at JPMorgan

Mar 11, 2026, 11:00 AM EDT - 3 months ago

Ultragenyx Pharmaceutical Transcript: Leerink Global Healthcare Conference 2026

Mar 10, 2026, 12:00 PM EDT - 3 months ago

Ultragenyx Pharmaceutical Transcript: Barclays 28th Annual Global Healthcare Conference

Mar 2, 2026, 1:50 PM EST - 4 months ago

Ultragenyx Pharmaceutical Transcript: TD Cowen 46th Annual Health Care Conference

Feb 24, 2026, 9:11 AM EST - 4 months ago

Ultragenyx Pharmaceutical Inc. (RARE) Securities Fraud: Contact Berger Montague To Discuss Your Rights

Feb 23, 2026, 4:30 PM EST - 4 months ago

Ultragenyx to Participate at Investor Conferences in March

Feb 23, 2026, 8:30 AM EST - 4 months ago

Ultragenyx Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application (BLA) for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)

Feb 18, 2026, 2:07 PM EST - 4 months ago

Stockholders Who Lost Money Investing in Ultragenyx Pharmaceutical Inc. Should Contact Robbins LLP for Information About Recovering Their Losses from RARE

Feb 12, 2026, 5:00 PM EST - 4 months ago

Ultragenyx Pharmaceutical Earnings Call Transcript: Q4 2025

Feb 12, 2026, 5:00 PM EST - 4 months ago

Ultragenyx Pharmaceutical Annual report: Q4 2025

Feb 12, 2026, 5:00 PM EST - 4 months ago

Ultragenyx Pharmaceutical Earnings release: Q4 2025

Feb 12, 2026, 4:01 PM EST - 4 months ago

Ultragenyx Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Update

Feb 12, 2026, 7:00 AM EST - 4 months ago

Ultragenyx Pharmaceutical Slides: Corporate presentation

Feb 9, 2026, 3:01 AM EST - 4 months ago

RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Lawsuit

Feb 3, 2026, 8:00 AM EST - 5 months ago

Ultragenyx Announces Positive Longer-Term Data Demonstrating Treatment with UX111 Gene Therapy Results in Sustained, Significant Reductions in CSF-HS and Continued Meaningful Improvements in Clinical Function Across Multiple Developmental Domains in Children with Sanfilippo Syndrome (MPS IIIA)

Jan 30, 2026, 8:30 AM EST - 5 months ago

Ultragenyx Resubmits Biologics License Application for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA) to U.S. FDA

Jan 23, 2026, 2:05 PM EST - 5 months ago

Ultragenyx Stock Declines After Missing Primary Endpoints on its Phase III Orbit and Cosmic Studies

Jan 12, 2026, 1:30 PM EST - 5 months ago

Ultragenyx Pharmaceutical Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 7:30 AM EST - 5 months ago

Ultragenyx Provides Financial and Business Updates at J.P. Morgan Annual Healthcare Conference

Jan 10, 2026, 7:00 AM EST - 5 months ago

Ultragenyx Pharmaceutical Slides: Corporate presentation

Dec 30, 2025, 4:05 PM EST - 6 months ago

Ultragenyx Completes Rolling Submission of Biologics License Application (BLA) to U.S. FDA for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)

Dec 30, 2025, 2:24 PM EST - 6 months ago

Ultragenyx Pharmaceutical, Inc. Investigated by the Portnoy Law Firm

Dec 29, 2025, 1:05 PM EST - 6 months ago

These biotech stocks are getting hammered by shocking brittle-bone treatment study results

MREO

Dec 29, 2025, 8:35 AM EST - 6 months ago

Ultragenyx's bone disease drug fails late-stage trials

Dec 29, 2025, 8:30 AM EST - 6 months ago

Ultragenyx Announces Phase 3 Orbit and Cosmic Results for Setrusumab (UX143) in Osteogenesis Imperfecta

Dec 3, 2025, 12:55 PM EST - 7 months ago

Ultragenyx Pharmaceutical Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 2, 2025, 3:15 PM EST - 7 months ago

Ultragenyx Pharmaceutical Transcript: Citi Annual Global Healthcare Conference 2025

Nov 4, 2025, 5:00 PM EST - 8 months ago

Ultragenyx Pharmaceutical Earnings Call Transcript: Q3 2025

Nov 4, 2025, 5:00 PM EST - 8 months ago

Ultragenyx Pharmaceutical Quarterly report: Q3 2025

Nov 4, 2025, 5:00 PM EST - 8 months ago

Ultragenyx Pharmaceutical Earnings release: Q3 2025

Nov 4, 2025, 4:01 PM EST - 8 months ago

Ultragenyx Announces Sale of a Portion of Future North American Royalties on Crysvita® (burosumab) for $400 Million to OMERS Life Sciences

Nov 3, 2025, 6:00 PM EST - 8 months ago

Ultragenyx Pharmaceutical Slides: Corporate Presentation

Oct 28, 2025, 4:30 PM EDT - 8 months ago

Ultragenyx to Host Conference Call for Third Quarter 2025 Financial Results and Corporate Update

Sep 30, 2025, 4:05 PM EDT - 9 months ago

Ultragenyx Appoints Eric Olson as Chief Business Officer and Executive Vice President

Sep 8, 2025, 4:05 PM EDT - 10 months ago

Ultragenyx Announces Positive Longer-term Data from Phase 3 Study of DTX401 AAV Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa)

Aug 29, 2025, 4:30 PM EDT - 10 months ago

Ultragenyx to Participate at Investor Conferences in September

Aug 18, 2025, 8:00 AM EDT - 11 months ago

Ultragenyx Initiates Rolling Submission of Biologics License Application (BLA) to U.S. FDA for DTX401 AAV Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa)

Aug 5, 2025, 5:00 PM EDT - 11 months ago

Ultragenyx Pharmaceutical Earnings Call Transcript: Q2 2025

Aug 5, 2025, 5:00 PM EDT - 11 months ago

Ultragenyx Pharmaceutical Quarterly report: Q2 2025

Aug 5, 2025, 5:00 PM EDT - 11 months ago

Ultragenyx Pharmaceutical Earnings release: Q2 2025

Aug 5, 2025, 5:00 PM EDT - 11 months ago

Ultragenyx Pharmaceutical Slides: Q2 2025

Aug 5, 2025, 4:01 PM EDT - 11 months ago

Ultragenyx Reports Second Quarter 2025 Financial Results and Corporate Update

Jul 30, 2025, 8:30 AM EDT - 11 months ago

Ultragenyx to Host Conference Call for Second Quarter 2025 Financial Results and Corporate Update

RandomInvestor777 Jun. 22 at 5:42 PM

$RARE Considering all patients would have be at 338 days at july, wouldn't readout be closer to early august? kindly anyone who's in depth about this company tell me if true or otherwise.

1 · Reply

Cascas007 Jun. 18 at 3:39 PM

$RARE This is a $15B company if Angelman phase 3 data comes out strong

0 · Reply

Pharma3000 Jun. 15 at 3:14 PM

$RARE

0 · Reply

Pharma3000 Jun. 15 at 3:13 PM

$RARE

0 · Reply

LDT79 Jun. 11 at 4:16 PM

$RARE if they raise they could buy $MREO for peanuts

1 · Reply

lonelywarrior Jun. 10 at 6:07 PM

$RARE Still cheap, good entry levels.

0 · Reply

AIBioScanner Jun. 8 at 7:58 AM

0 · Reply

LDT79 Jun. 3 at 6:36 PM

$RARE can this thing stop fading every fucking morning?

0 · Reply

traderjon01 Jun. 3 at 5:29 PM

0 · Reply

LDT79 Jun. 2 at 3:43 PM

$RARE fuck is going on here?? Emil Kakkis, get shit done my man!!!

0 · Reply

beachlife2103 Jun. 2 at 2:33 PM

$SGMO $QURE $SRPT $RGNX $RARE

0 · Reply

biotech Jun. 2 at 2:25 PM

$SGMO $QURE $SRPT $RGNX $RARE FDA Acting Head to Meet Closed-Door With Rare Disease Groups scheduled for Wednesday, Kyle Diamantas and other senior agency officials will meet with at least 10 rare disease groups for a private conversation about advancing treatments Diamantas has made it a #priority to meet with as many parties as possible, especially #rare disease groups https://news.bloomberglaw.com/health-law-and-business/fdas-acting-head-to-meet-closed-door-with-rare-disease-groups

1 · Reply

LDT79 Jun. 1 at 2:32 PM

$RARE no volume shorting plus XBI shitting the bed?

0 · Reply

urban979 May. 31 at 5:24 PM

$RARE Late-stage gene therapy pipeline.!!

0 · Reply

elmono May. 30 at 8:27 AM

$RARE the problem I have with this company is they are overspending…they should be more cash conservative to create a viable business instead of continuing to push that out into the future. Unfortunately we will see another offering before YE, probably another 25% dilution. This holds the sp back a bit

0 · Reply

LDT79 May. 28 at 3:54 PM

$RARE $96 price target = 3.5x

0 · Reply

anachartanalyst May. 21 at 4:02 PM

$RARE https://anachart.com/wp-content/uploads/2026/05/1779379311_soc-img.jpg

0 · Reply

JohnPine1 May. 21 at 2:27 PM

$RARE Cantor Fitzgerald raises to $96

0 · Reply

TKkamen May. 19 at 7:40 PM

$RARE What are the odds of approval?

1 · Reply

lonelywarrior May. 19 at 5:37 PM

$RARE Good levels to buy here.

1 · Reply

JFais May. 14 at 1:55 PM

$RARE's partner $MREO jumping the gun a bit (in a good way) Sounds like there may indeed be a path forward for setrusumab in OI in the pediatric population Regulatory interactions initiated, updates to be provided after feedback received Clear separation in the COSMIC study🧐

0 · Reply

BillionerOfKing May. 11 at 2:47 PM

$RARE Current Stock Price: $27.29 Contracts to trade: $27.5 RARE May 15 2026 Call Entry: $0.25 Exit: $0.42 ROI: 69% Hold ~29 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

Market Cap	2.70B
Revenue (ttm)	673.00M
Net Income (ttm)	-575.00M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-85.44%
Debt to Equity Ratio	0.00

Volume	1,209,410
Avg Vol	1,741,886
Day's Range	N/A - N/A
Shares Out	98.49M
Stochastic %K	96%
Beta	0.37
Analysts	Strong Sell
Price Target	$52.05